327 related articles for article (PubMed ID: 29486761)
1. Impaired diversity of the lung microbiome predicts progression of idiopathic pulmonary fibrosis.
Takahashi Y; Saito A; Chiba H; Kuronuma K; Ikeda K; Kobayashi T; Ariki S; Takahashi M; Sasaki Y; Takahashi H
Respir Res; 2018 Feb; 19(1):34. PubMed ID: 29486761
[TBL] [Abstract][Full Text] [Related]
2. Lung Microbiota Contribute to Pulmonary Inflammation and Disease Progression in Pulmonary Fibrosis.
O'Dwyer DN; Ashley SL; Gurczynski SJ; Xia M; Wilke C; Falkowski NR; Norman KC; Arnold KB; Huffnagle GB; Salisbury ML; Han MK; Flaherty KR; White ES; Martinez FJ; Erb-Downward JR; Murray S; Moore BB; Dickson RP
Am J Respir Crit Care Med; 2019 May; 199(9):1127-1138. PubMed ID: 30789747
[No Abstract] [Full Text] [Related]
3. Topographic heterogeneity of lung microbiota in end-stage idiopathic pulmonary fibrosis: the Microbiome in Lung Explants-2 (MiLEs-2) study.
Valenzi E; Yang H; Sembrat JC; Yang L; Winters S; Nettles R; Kass DJ; Qin S; Wang X; Myerburg MM; Methé B; Fitch A; Alder JK; Benos PV; McVerry BJ; Rojas M; Morris A; Kitsios GD
Thorax; 2021 Mar; 76(3):239-247. PubMed ID: 33268457
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of surfactant protein A, surfactant protein D, Clara cell protein 16, S100 protein, trefoil factor 3, and prostatic secretory protein 94 in idiopathic pulmonary fibrosis, sarcoidosis, and chronic pulmonary obstructive disease.
Doubková M; Karpíšek M; Mazoch J; Skřičková J; Doubek M
Sarcoidosis Vasc Diffuse Lung Dis; 2016 Oct; 33(3):224-234. PubMed ID: 27758987
[TBL] [Abstract][Full Text] [Related]
5. Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis.
Reichmann WM; Yu YF; Macaulay D; Wu EQ; Nathan SD
BMC Pulm Med; 2015 Dec; 15():167. PubMed ID: 26714746
[TBL] [Abstract][Full Text] [Related]
6. The Lung Microbiome in Idiopathic Pulmonary Fibrosis: A Promising Approach for Targeted Therapies.
Fastrès A; Felice F; Roels E; Moermans C; Corhay JL; Bureau F; Louis R; Clercx C; Guiot J
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29258183
[TBL] [Abstract][Full Text] [Related]
7. EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis.
Doubková M; Švancara J; Svoboda M; Šterclová M; Bartoš V; Plačková M; Lacina L; Žurková M; Binková I; Bittenglová R; Lošťáková V; Merta Z; Šišková L; Tyl R; Lisá P; Šuldová H; Petřík F; Pšikalová J; Řihák V; Snížek T; Reiterer P; Homolka J; Musilová P; Lněnička J; Palúch P; Hrdina R; Králová R; Hortvíková H; Strenková J; Vašáková M
Clin Respir J; 2018 Apr; 12(4):1526-1535. PubMed ID: 28862397
[TBL] [Abstract][Full Text] [Related]
8. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis.
Molyneaux PL; Cox MJ; Willis-Owen SA; Mallia P; Russell KE; Russell AM; Murphy E; Johnston SL; Schwartz DA; Wells AU; Cookson WO; Maher TM; Moffatt MF
Am J Respir Crit Care Med; 2014 Oct; 190(8):906-13. PubMed ID: 25184687
[TBL] [Abstract][Full Text] [Related]
9. Disease progression in idiopathic pulmonary fibrosis without pulmonary function impairment.
Kondoh Y; Taniguchi H; Ogura T; Johkoh T; Fujimoto K; Sumikawa H; Kataoka K; Baba T; Colby TV; Kitaichi M
Respirology; 2013 Jul; 18(5):820-6. PubMed ID: 23489318
[TBL] [Abstract][Full Text] [Related]
10. The Respiratory Microbiome in Chronic Hypersensitivity Pneumonitis Is Distinct from That of Idiopathic Pulmonary Fibrosis.
Invernizzi R; Wu BG; Barnett J; Ghai P; Kingston S; Hewitt RJ; Feary J; Li Y; Chua F; Wu Z; Wells AU; George PM; Renzoni EA; Nicholson AG; Rice A; Devaraj A; Segal LN; Byrne AJ; Maher TM; Lloyd CM; Molyneaux PL
Am J Respir Crit Care Med; 2021 Feb; 203(3):339-347. PubMed ID: 32692582
[No Abstract] [Full Text] [Related]
11. Matrix metalloproteinase-10: a novel biomarker for idiopathic pulmonary fibrosis.
Sokai A; Handa T; Tanizawa K; Oga T; Uno K; Tsuruyama T; Kubo T; Ikezoe K; Nakatsuka Y; Tanimura K; Muro S; Hirai T; Nagai S; Chin K; Mishima M
Respir Res; 2015 Sep; 16():120. PubMed ID: 26415518
[TBL] [Abstract][Full Text] [Related]
12. Lung Tissue Microbiome Is Associated With Clinical Outcomes of Idiopathic Pulmonary Fibrosis.
Yoon HY; Moon SJ; Song JW
Front Med (Lausanne); 2021; 8():744523. PubMed ID: 34733866
[No Abstract] [Full Text] [Related]
13. Alterations to the Lung Microbiome in Idiopathic Pulmonary Fibrosis Patients.
Tong X; Su F; Xu X; Xu H; Yang T; Xu Q; Dai H; Huang K; Zou L; Zhang W; Pei S; Xiao F; Li Y; Wang C
Front Cell Infect Microbiol; 2019; 9():149. PubMed ID: 31165050
[TBL] [Abstract][Full Text] [Related]
14. Lipocalin-2 as a prognostic marker in patients with acute exacerbation of idiopathic pulmonary fibrosis.
Tanahashi H; Iwamoto H; Yamaguchi K; Sakamoto S; Horimasu Y; Masuda T; Nakashima T; Ohshimo S; Fujitaka K; Hamada H; Hattori N
Respir Res; 2024 May; 25(1):195. PubMed ID: 38704585
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D prevents experimental lung fibrosis and predicts survival in patients with idiopathic pulmonary fibrosis.
Tzilas V; Bouros E; Barbayianni I; Karampitsakos T; Kourtidou S; Ntassiou M; Ninou I; Aidinis V; Bouros D; Tzouvelekis A
Pulm Pharmacol Ther; 2019 Apr; 55():17-24. PubMed ID: 30659895
[TBL] [Abstract][Full Text] [Related]
16. Role of lung apolipoprotein A-I in idiopathic pulmonary fibrosis: antiinflammatory and antifibrotic effect on experimental lung injury and fibrosis.
Kim TH; Lee YH; Kim KH; Lee SH; Cha JY; Shin EK; Jung S; Jang AS; Park SW; Uh ST; Kim YH; Park JS; Sin HG; Youm W; Koh ES; Cho SY; Paik YK; Rhim TY; Park CS
Am J Respir Crit Care Med; 2010 Sep; 182(5):633-42. PubMed ID: 20463180
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics of patients with familial idiopathic pulmonary fibrosis (f-IPF).
Krauss E; Gehrken G; Drakopanagiotakis F; Tello S; Dartsch RC; Maurer O; Windhorst A; von der Beck D; Griese M; Seeger W; Guenther A
BMC Pulm Med; 2019 Jul; 19(1):130. PubMed ID: 31319833
[TBL] [Abstract][Full Text] [Related]
18. Idiopathic Pulmonary Fibrosis: Prospective, Case-Controlled Study of Natural History and Circulating Biomarkers.
Raghu G; Richeldi L; Jagerschmidt A; Martin V; Subramaniam A; Ozoux ML; Esperet CA; Soubrane C
Chest; 2018 Dec; 154(6):1359-1370. PubMed ID: 30526970
[TBL] [Abstract][Full Text] [Related]
19. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study.
Han MK; Zhou Y; Murray S; Tayob N; Noth I; Lama VN; Moore BB; White ES; Flaherty KR; Huffnagle GB; Martinez FJ;
Lancet Respir Med; 2014 Jul; 2(7):548-56. PubMed ID: 24767767
[TBL] [Abstract][Full Text] [Related]
20. S100A9 in BALF is a candidate biomarker of idiopathic pulmonary fibrosis.
Hara A; Sakamoto N; Ishimatsu Y; Kakugawa T; Nakashima S; Hara S; Adachi M; Fujita H; Mukae H; Kohno S
Respir Med; 2012 Apr; 106(4):571-80. PubMed ID: 22209187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
